Safety and Efficacy Reconyl for Cough With/Without Sore Throat
NCT06510257 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2025-02-07
Summary
This study is a prospective, randomized, double-blind and placebo-controlled study to find out if reconyl may relieve the acute cough with/without sore throat.
Conditions
Interventions
- DRUG
-
Reconyl
1 tablet of Reconyl, 3 times daily
- DRUG
-
Placebo tablet of Reconyl
1 tablet of placebo Reconyl, 3 times daily
Sponsors & Collaborators
-
Fakultas Kedokteran Universitas Indonesia
collaborator OTHER -
Dexa Medica Group
lead INDUSTRY
Principal Investigators
-
Dewi S Rosdiana, Dr,MD,MKes · Department Pharmacology & Therapeutics Faculty of Medicine Universitas Indonesia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-23
- Primary Completion
- 2024-09-30
- Completion
- 2024-10-03
Countries
- Indonesia
Study Locations
More Related Trials
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
NCT06754605 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
NCT02114268 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
NCT02298179 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
NCT02601612 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
NCT05381519 ·Status: UNKNOWN ·Phase: PHASE2
-
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
NCT05918939 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
NCT04442230 ·Status: TERMINATED ·Phase: PHASE2
-
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
NCT04690387 ·Status: COMPLETED ·Phase: PHASE1
-
An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults
NCT03334695 ·Status: COMPLETED ·Phase: PHASE2
-
rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19
NCT05485584 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of AK0529 in Adults Patients Hospitalized With RSV Infection
NCT06942299 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
NCT06085924 ·Status: COMPLETED
-
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers
NCT02561871 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
NCT04583280 ·Status: TERMINATED ·Phase: PHASE3
-
Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
NCT05574985 ·Status: COMPLETED ·Phase: NA
-
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
NCT06259578 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)
NCT05084989 ·Status: COMPLETED ·Phase: PHASE2
-
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
NCT02254408 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
NCT05941793 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
NCT04520659 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19
NCT05054114 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above
NCT06642558 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age
NCT01754428 ·Status: COMPLETED
-
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
NCT06775405 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
NCT04505722 ·Status: COMPLETED ·Phase: PHASE3